Unusual case of drug-induced cholestasis due to glucosamine and chondroitin sulfate

被引:0
作者
Stephen Ip [1 ]
Rachel Jeong [2 ]
David F Schaeffer [3 ]
Eric M Yoshida [1 ]
机构
[1] Division of Gastroenterology,Vancouver General Hospital,University of British Columbia
[2] Faculty of Medicine and Dentistry,University of Alberta
[3] Department of Pathology and Laboratory Medicine,University of British Columbia
关键词
Glucosamine; Chondroitin; Hepatotoxicity; Cholestasis; Jaundice;
D O I
暂无
中图分类号
R575 [肝及胆疾病];
学科分类号
1002 ; 100201 ;
摘要
Glucosamine(GS) and chondroitin sulfate(CS) are common over-the-counter(OTC) supplements used in the treatment of osteoarthritis. These medications are seemingly safe, but there are increasing reports of hepatotoxicity with these supplements. We reported a unique case of drug-induced cholestasis caused by GS and CS in a combination tablet. The etiology of the jaundice was overlooked despite extensive investigations over a three-month period. Unlike drug-induced hepatocellular injury, drug-induced cholestatic jaundice with GS and CS has only been reported twice before. This case emphasizes the importance of a complete medication history, especially OTC supplements, in the assessment of cholestasis.
引用
收藏
页码:2559 / 2562
页数:4
相关论文
共 50 条
  • [41] Population pharmacokinetic model to generate mechanistic insights in bile acid homeostasis and drug-induced cholestasis
    de Bruijn, Veronique M. P.
    Rietjens, Ivonne M. C. M.
    Bouwmeester, Hans
    ARCHIVES OF TOXICOLOGY, 2022, 96 (10) : 2717 - 2730
  • [43] Semi-automated approach for generation of biological networks on drug-induced cholestasis, steatosis, hepatitis, and cirrhosis
    Shin, Hyun Kil
    Florean, Oana
    Hardy, Barry
    Doktorova, Tatyana
    Kang, Myung-Gyun
    TOXICOLOGICAL RESEARCH, 2022, 38 (03) : 393 - 407
  • [44] Drug-induced cholestasis (DIC) predictions based on in vitro inhibition of major bile acid clearance mechanisms
    Kastrinou-Lampou, Vlasia
    Rodriguez-Perez, Raquel
    Poller, Birk
    Huth, Felix
    Schadt, Heiko S.
    Kullak-Ublick, Gerd A.
    Arand, Michael
    Camenisch, Gian
    ARCHIVES OF TOXICOLOGY, 2025, 99 (01) : 377 - 391
  • [45] Semi-automated approach for generation of biological networks on drug-induced cholestasis, steatosis, hepatitis, and cirrhosis
    Hyun Kil Shin
    Oana Florean
    Barry Hardy
    Tatyana Doktorova
    Myung-Gyun Kang
    Toxicological Research, 2022, 38 : 393 - 407
  • [46] Case Definition and Phenotype Standardization in Drug-Induced Liver Injury
    Aithal, G. P.
    Watkins, P. B.
    Andrade, R. J.
    Larrey, D.
    Molokhia, M.
    Takikawa, H.
    Hunt, C. M.
    Wilke, R. A.
    Avigan, M.
    Kaplowitz, N.
    Bjornsson, E.
    Daly, A. K.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 (06) : 806 - 815
  • [47] Drug-Induced Liver Injury due to Biologics and Immune Check Point Inhibitors
    Bessone, Fernando
    Bjornsson, Einar S.
    MEDICAL CLINICS OF NORTH AMERICA, 2023, 107 (03) : 623 - 640
  • [48] Drug-Induced Liver Injury Due to Nonsteroidal Anti-inflammatory Drugs
    Schmeltzer P.A.
    Current Hepatology Reports, 2019, 18 (3) : 294 - 299
  • [49] Pyrazinamide related prolonged drug-induced liver injury: A case report
    Wang, Yeh-Chin
    Chen, Kai-Hsiang
    Chen, Yen-Lin
    Lin, Shu-Wen
    Liu, Wang-Da
    Wang, Jann-Tay
    Hung, Chien-Ching
    MEDICINE, 2022, 101 (39) : E30955
  • [50] Vedolizumab-Associated Drug-Induced Liver Injury: A Case Series
    Honap, Sailish
    Sticova, Eva
    Theocharidou, Eleni
    Berry, Philip
    Irving, Peter M.
    Samaan, Mark A.
    Kotha, Sreelakshmi
    INFLAMMATORY BOWEL DISEASES, 2021, 27 (03) : E32 - E34